THREAT helps to identify epistaxis patients requiring blood transfusions

Karin Murer, Nader Ahmad, Beatrice A Roth, David Holzmann, Michael B Soyka, Karin Murer, Nader Ahmad, Beatrice A Roth, David Holzmann, Michael B Soyka

Abstract

Objective: To analyze the characteristics of patients who needed a blood transfusion due to epistaxis-caused anemia and to define potential risk factors.

Design: Retrospective cohort study.

Setting: A total cohort of 591 epistaxis patients, prospectively included between March 2007 and April 2008 at the ENT department of the University Hospital of Zurich, was evaluated concerning the need for blood transfusions.

Methods: The clinical charts and medical histories of these patients were evaluated.

Main outcome measures: Common parameters that increase the risk for severe anemia due to epistaxis.

Results: Twenty-two patients required blood transfusions due to their medical condition. 22.7% suffered from traumatic nosebleeds. Another 27.3% had a known medical condition with an increased bleeding tendency. These proportions were significantly higher than in the group of patients without need of blood transfusion. The odds ratio for receiving a blood transfusion was 14.0 in patients with hematologic disorders, 4.3 in traumatic epistaxis and 7.7 in posterior bleeders. The transfusion-dependent epistaxis patients suffered significantly more often from severe posterior nosebleeds with the need for a surgical therapeutic approach.

Conclusions: Patients with severe nosebleeds either from the posterior part of the nose or with known hematologic disorders or traumatic epistaxis should be closely monitored by blood parameter analyses to evaluate the indication for hemotransfusion. The acronym THREAT (Trauma, Hematologic disorder, and REAr origin of bleeding → Transfusion) helps to remember and identify the factors associated with an increased risk of receiving blood transfusion.

References

    1. Soyka MB, Rufibach K, Huber A. et severe epistaxis associated with acetylsalicylic acid intake? Laryngoscope. 2010;120(1):200–207.
    1. Klossek JM, Dufour X, de Montreuil CB. et al.Epistaxis and its management: an observational pilot study carried out in 23 hospital centres in France. Rhinology. 2006;44(2):151–155.
    1. Pollice PA, Yoder MG. Epistaxis: a retrospective review of hospitalized patients. Otolaryngology--head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery. 1997;117(1):49–53. doi: 10.1016/S0194-5998(97)70205-5.
    1. Douglas R, Wormald PJ. Update on epistaxis. Curr Opin Otolaryngol Head Neck Surg. 2007;15(3):180–183. doi: 10.1097/MOO.0b013e32814b06ed.
    1. Hebert PC, Wells G, Blajchman MA. et al.A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in critical care investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340(6):409–417. doi: 10.1056/NEJM199902113400601.
    1. Marshall JC. Transfusion trigger: when to transfuse? Crit Care. 2004;8(Suppl 2):S31–33. doi: 10.1186/cc2846.
    1. Carless PA, Henry DA, Carson JL. et al.Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2010;6(10):CD002042.
    1. Folz BJ, Kanne M, Werner JA. Current aspects in epistaxis. HNO. 2008;56(11):1157–1165. doi: 10.1007/s00106-008-1838-3. quiz 1166.
    1. Fuchs FD, Moreira LB, Pires CP. et al.Absence of association between hypertension and epistaxis: a population-based study. Blood Press. 2003;12(3):145–148. doi: 10.1080/08037050310001750.
    1. Lubianca Neto JF, Fuchs FD, Facco SR. et epistaxis evidence of end-organ damage in patients with hypertension? Laryngoscope. 1999;109(7 Pt 1):1111–1115.
    1. Knopfholz J, Lima-Junior E, Precoma-Neto D. et al.Association between epistaxis and hypertension: a one year follow-up after an index episode of nose bleeding in hypertensive patients. Int J Cardiol. 2009;134(3):e107–109. doi: 10.1016/j.ijcard.2008.01.018.
    1. Celik T, Iyisoy A, Yuksel UC. et al.A new evidence of end-organ damage in the patients with arterial hypertension: epistaxis? Int J Cardiol. 2010;141(1):105–107. doi: 10.1016/j.ijcard.2008.11.090.
    1. Page C, Biet A, Liabeuf S. et al.Serious spontaneous epistaxis and hypertension in hospitalized patients. Eur Arch Otorhinolaryngol. 2011;268(12):1749–53. doi: 10.1007/s00405-011-1659-y.
    1. Joice P, Ross P, Robertson G. et al.The effect of hand dominance on recurrent idiopathic paediatric epistaxis. Clin Otolaryngol. 2008;33(6):570–574. doi: 10.1111/j.1749-4486.2008.01831.x.
    1. Soyka MB, Nikolaou G, Rufibach K. et al.On the effectiveness of treatment options in epistaxis: an analysis of 678 interventions. Rhinology. 2011;49(4):474–478.
    1. Morera E, Artigas C, Ferran L. et al.Transcaruncular electrocoagulation of anterior ethmoidal artery for the treatment of severe epistaxis. Laryngoscope. 2011;121(2):446–450. doi: 10.1002/lary.21372.
    1. R Development Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria 2008.
    1. Barlow DW, Deleyiannis WB, Pinczower EF. Effectiveness of surgical management of epistaxis at a tertiary care center. Laryngoscope. 1997;107(1):21–24. doi: 10.1097/00005537-199701000-00007.
    1. Voegels RL, Thome DC, Iturralde PP. et al.Endoscopic ligature of the sphenopalatine artery for severe posterior epistaxis. Otolaryngology--head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2001;124(4):464–467. doi: 10.1067/mhn.2001.113512.
    1. McFarland JG. Perioperative blood transfusions: indications and options. Chest. 1999;115(5 Suppl):113S–121S.
    1. Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev. 2010;24(2):77–124. doi: 10.1016/j.tmrv.2009.11.001.
    1. Carson JL, Hill S, Carless P. et al.Transfusion triggers: a systematic review of the literature. Transfus Med Rev. 2002;16(3):187–199. doi: 10.1053/tmrv.2002.33461.
    1. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333(14):918–924. doi: 10.1056/NEJM199510053331407.
    1. Larson RA. Myelodysplasia: when to treat and how. Best Pract Res Clin Haematol. 2006;19(2):293–300. doi: 10.1016/j.beha.2005.11.005.
    1. Coppola A, Tufano A, Di Capua M. et al.Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost. 2011;37(8):929–945. doi: 10.1055/s-0031-1297372.
    1. Hauswirth AW, Skrabs C, Schutzinger C. et al.Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica. 2008;93(3):447–450. doi: 10.3324/haematol.11934.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever